Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Mar 27 04:00PM ET
2.19
Dollar change
+0.08
Percentage change
3.79
%
Index- P/E- EPS (ttm)-0.02 Insider Own1.77% Shs Outstand67.31M Perf Week-3.52%
Market Cap148.31M Forward P/E- EPS next Y-0.44 Insider Trans-5.93% Shs Float66.52M Perf Month-2.67%
Income-0.57M PEG- EPS next Q-0.08 Inst Own48.31% Short Float5.31% Perf Quarter47.97%
Sales101.21M P/S1.47 EPS this Y-3066.67% Inst Trans-20.06% Short Ratio3.99 Perf Half Y73.81%
Book/sh-0.70 P/B- EPS next Y-37.53% ROA-0.24% Short Interest3.53M Perf Year22.35%
Cash/sh2.58 P/C0.85 EPS next 5Y-0.90% ROE-4417.92% 52W Range1.04 - 2.86 Perf YTD41.29%
Dividend Est.- P/FCF- EPS past 5Y67.21% ROI- 52W High-23.29% Beta1.01
Dividend TTM- Quick Ratio1.17 Sales past 5Y28.25% Gross Margin95.12% 52W Low110.58% ATR (14)0.18
Dividend Ex-Date- Current Ratio1.17 EPS Y/Y TTM98.62% Oper. Margin1.47% RSI (14)53.64 Volatility5.44% 9.45%
Employees122 Debt/Eq- Sales Y/Y TTM39.92% Profit Margin-0.56% Recom2.83 Target Price2.85
Option/ShortYes / Yes LT Debt/Eq- EPS Q/Q109.36% Payout- Rel Volume0.67 Prev Close2.11
Sales Surprise35.79% EPS Surprise141.41% Sales Q/Q32.22% EarningsMar 11 AMC Avg Volume885.83K Price2.19
SMA20-6.45% SMA5017.03% SMA20039.73% Trades Volume590,298 Change3.79%
Date Action Analyst Rating Change Price Target Change
Nov-14-22Downgrade BMO Capital Markets Outperform → Market Perform $3 → $2.60
Jul-07-22Downgrade Wedbush Outperform → Neutral $6 → $2
Jul-07-22Downgrade Piper Sandler Overweight → Neutral $10 → $1.50
Jul-07-22Downgrade Mizuho Buy → Neutral $16 → $4
Jul-07-22Downgrade Jefferies Buy → Hold $12 → $2
Jun-24-22Initiated BMO Capital Markets Outperform $9
Jan-18-22Upgrade Barclays Underweight → Overweight $7
Nov-15-21Initiated BTIG Research Buy $16
May-28-21Downgrade Barclays Equal Weight → Underweight $9 → $7
Mar-29-21Initiated JP Morgan Overweight $14
Mar-21-24 08:00AM
Mar-18-24 08:00AM
Mar-12-24 09:12AM
08:30AM
06:46AM
05:34PM Loading…
Mar-11-24 05:34PM
05:20PM
04:10PM
Mar-04-24 08:00AM
Feb-27-24 11:52AM
08:00AM
Jan-24-24 08:00AM
Jan-12-24 08:00AM
Jan-04-24 08:00AM
Dec-21-23 08:00AM
12:00PM Loading…
Nov-13-23 12:00PM
Nov-08-23 10:15AM
Nov-07-23 05:05PM
04:15PM
Nov-01-23 08:00AM
Oct-31-23 08:00AM
Oct-30-23 08:00AM
Oct-18-23 04:30PM
Sep-05-23 04:05PM
Aug-25-23 09:35AM
Aug-10-23 04:05PM
Aug-08-23 05:30PM
04:26PM
04:15PM
Aug-01-23 08:00AM
09:00AM Loading…
Jul-20-23 09:00AM
Jul-17-23 08:00AM
Jun-30-23 08:00AM
Jun-08-23 09:02AM
Jun-01-23 04:05PM
May-11-23 06:05AM
May-10-23 08:13AM
May-09-23 05:35PM
04:26PM
04:15PM
May-05-23 06:34AM
May-01-23 04:01PM
10:01AM
Apr-27-23 10:03AM
Apr-25-23 04:05PM
Mar-30-23 11:26AM
Mar-29-23 06:06AM
Mar-28-23 01:35PM
Mar-27-23 05:35PM
04:15PM
Mar-22-23 07:23PM
Mar-20-23 06:14AM
Feb-28-23 04:05PM
Feb-07-23 06:07AM
Jan-26-23 07:00AM
Jan-17-23 04:05PM
Jan-12-23 05:30AM
Jan-06-23 06:44PM
01:46PM
10:30AM
Jan-05-23 05:11PM
04:19PM
04:05PM
04:05PM
Dec-22-22 05:00PM
07:54AM
Dec-20-22 05:00PM
Dec-07-22 04:30PM
Nov-23-22 12:18PM
Nov-18-22 01:18PM
Nov-17-22 11:14AM
11:09AM
07:00AM
07:00AM
Nov-08-22 05:35PM
04:10PM
Nov-07-22 04:15PM
Nov-02-22 04:15PM
Nov-01-22 08:00AM
Oct-27-22 05:15PM
Sep-13-22 08:42AM
Sep-12-22 08:00AM
Sep-07-22 06:05PM
Sep-01-22 10:17AM
Aug-05-22 08:30AM
Aug-04-22 05:45PM
04:15PM
Aug-03-22 08:00AM
Aug-01-22 10:01AM
Jul-28-22 10:02AM
08:00AM
Jul-15-22 10:50AM
07:54AM
Jul-14-22 06:05AM
Jul-13-22 04:05PM
Jul-07-22 06:15AM
Jul-06-22 04:05PM
Jun-27-22 08:33AM
Jun-16-22 08:00AM
Jun-01-22 08:00AM
CytomX Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company, which engages in the development of conditionally activated, biologics localized to the tumor microenvironment. The company was founded by Frederick W. Gluck and Nancy E. Stagliano in September 2010 and is headquartered in South San Francisco, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
McCarthy Sean A.CEOMar 19 '24Sale2.0920,22342,175524,481Mar 21 04:40 PM
BELVIN MARCIASVP, Chief Scientific OfficerMar 19 '24Sale2.0912,79526,684168,579Mar 21 04:37 PM
Landau Jeffrey BChief Business OfficerMar 19 '24Sale2.096,56213,685110,060Mar 21 04:36 PM
ROWLAND LLOYD AGeneral CounselMar 19 '24Sale2.095,26810,986117,728Mar 21 04:41 PM
Ogden ChristopherSVP, Finance and AccountingMar 19 '24Sale2.092,9716,19685,686Mar 21 04:38 PM
McCarthy Sean A.CEODec 20 '23Sale1.3813,55118,710454,704Dec 22 04:16 PM
ROWLAND LLOYD AGeneral CounselDec 20 '23Sale1.384,0775,62997,996Dec 22 04:11 PM
BELVIN MARCIASVP, Chief Scientific OfficerDec 20 '23Sale1.384,0775,628155,124Dec 22 04:14 PM
Landau Jeffrey BChief Business OfficerDec 20 '23Sale1.384,0775,62886,622Dec 22 04:12 PM
Ogden ChristopherSVP, Finance and AccountingDec 20 '23Sale1.381,9902,74748,657Dec 22 04:10 PM
Ogden ChristopherSVP, Finance and AccountingDec 17 '23Option Exercise0.006,875050,647Dec 19 07:58 PM
McCarthy Sean A.CEODec 17 '23Option Exercise0.0037,5000468,255Dec 19 07:57 PM
Landau Jeffrey BChief Business OfficerDec 17 '23Option Exercise0.0011,250090,699Dec 19 07:56 PM
ROWLAND LLOYD AGeneral CounselDec 17 '23Option Exercise0.0011,2500102,073Dec 19 07:55 PM
BELVIN MARCIASVP, Chief Scientific OfficerDec 17 '23Option Exercise0.0011,2500159,201Dec 19 07:54 PM
McCarthy Sean A.CEOSep 22 '23Sale1.3014,60118,987430,755Sep 22 07:13 PM
ROWLAND LLOYD AGeneral CounselSep 22 '23Sale1.305,4867,13580,609Sep 22 07:12 PM
BELVIN MARCIASVP, Chief Scientific OfficerSep 22 '23Sale1.304,1195,356147,951Sep 22 07:16 PM
Landau Jeffrey BChief Business OfficerSep 22 '23Sale1.304,1195,35676,379Sep 22 07:15 PM
McCarthy Sean A.CEOMay 19 '23Option Exercise1.5716,53526,041405,356May 23 04:52 PM
Jones Elaine VDirectorMar 29 '23Buy1.555,0007,7505,142Mar 31 07:56 PM